Celltrion

Dear Shareholders,

On July 9, 2025 (Korea Standard Time), U.S. President Donald Trump stated that his administration is considering imposing tariffs on pharmaceuticals, with a grace period of up to 18 months.

Our company has been continuously monitoring developments regarding the potential imposition of U.S. pharmaceutical tariffs and has prepared response strategies for various scenarios to minimize potential impact.

As previously announced, the key points of our response strategy are as follows:

Short-term: We have already secured a two-year inventory supply and plan to maintain this two-year inventory on a rolling basis going forward.

Mid-term: We have finalized contracts with local CMO (Contract Manufacturing Organization) partners to enable local production of products sold in the U.S.

Long-term: We are currently reviewing the acquisition of a company with manufacturing facilities in the U.S., and we will promptly provide further details to our shareholders once the matter becomes more concrete.

As shared during the investor day in May, we are systematically implementing our response plan not only for the short term but also for the mid to long term. Regardless of when or to what extent the U.S. pharmaceutical tariff policy is finalized, our goal is to have all necessary preparations in place by the end of next year to ensure minimal impact on our business.

We will continue to keep our shareholders informed of all relevant developments and strive to maintain your trust and support for the company.

Thank you.